Accendra Health (ACH) Q2 2026 Earnings Call Transcript
Accendra Health (ACH) reported Q2 2026 net revenue of $613.2 million, down from $681.9 million a year earlier, and adjusted EBITDA of $60.1 million versus $96.6 million. Full-year revenue guidance was revised to $2.45 billion to $2.55 billion and adjusted EBITDA to $300 million to $320 million. Debt fell to $1.72 billion as of June 30, 2026.
How this was made
The 30-second read
Why it matters
Management reported Q2 results below internal expectations and revised full-year guidance downward, citing slower revenue growth and delayed collection rates. The company also detailed debt reduction and maturity extension, a planned NOL rights plan, and an ATM equity program to reduce indebtedness.
Market read
Traders can update models for ACH based on the revised revenue and adjusted EBITDA ranges, the quantified $20M collection-rate drag, and the stated path to breakeven-to-slightly-positive free cash flow in 2026.
What to watch
Accounts receivable rose to $120.1M due to inefficient payor audit processes, and cash interest is set to increase in December, both of which can dominate near-term free cash flow even if operating categories grow.
Background
Accendra Health is transitioning into a pure-play home-based healthcare provider after separation from Owens & Minor, with ongoing operational transformation and payor reimbursement collection challenges.
Ticker impact
Accendra Health guided full-year revenue to $2.45B-$2.55B and adjusted EBITDA to $300M-$320M after a $20M first-half collection-rate drag.
Near-term downside risk as investors reprice slower collections and margin pressure, partially offset by the $385M debt reduction and extended maturities.
Multiple forward-looking datapoints were provided (revised revenue and EBITDA ranges, FCF breakeven-to-slightly-positive, cash interest increase, and $20M collection drag). These are direct drivers of earnings power and credit risk, though the company also highlighted cost eliminations and balance-sheet optimization.
Market effects
Home-based healthcare and DME providers may face similar payor collection-rate and audit-process efficiency risks, affecting sector margin expectations.
Primarily US commercial payor reimbursement dynamics; limited direct regional spillover beyond US healthcare services.
Low global relevance; the drivers are US reimbursement and company-specific balance-sheet actions.
Counterpoint
The guidance reset may be conservative and temporary if the Sleep Center of Excellence rollout and the early-2027 sole-source health system agreement accelerate collections and reduce working-capital drag.
Key entities
- companyAccendra Health, Inc.
Reported Q2 2026 results and revised full-year revenue, adjusted EBITDA, and free cash flow outlook; discussed payor collection headwinds and balance-sheet actions.
- executiveEdward Pesicka
CEO who announced intention to retire by end of 2026 and discussed transformation progress and rollout timing.
- executiveJonathan Leon
CFO who quantified collection-rate drag, guided adjusted EBITDA, and described the NOL rights plan and liquidity/interest dynamics.
